Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.36−0.51 (-4.69%)
Close on Nov 13, 2026Market cap $595.04MP/E –Yield –
Climb Bio enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Climb Bio's enterprise value was $520.47M on Nov 11, 2026, against $41.97M a year earlier. Over the last 5 years it ranged from -$77.45M to $605.48M, with a median of -$14.27M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $520.47M | +180.1% |
| 2025 | Dec 31, 2025 | $185.84M | – |
| 2024 | Dec 31, 2024 | -$72.35M | – |
| 2023 | Dec 29, 2023 | -$33.27M | – |
| 2022 | Dec 30, 2022 | -$25.12M | -119.6% |
| 2021 | Dec 31, 2021 | $128.03M | – |
See a number that looks wrong?